Article Text

Download PDFPDF
miR-29b Expression Is Associated With Disease-Free Survival in Patients With Ovarian Serous Carcinoma
  1. Richard Flavin, FRCPath*,
  2. Paul Smyth, PhD*,
  3. Ciara Barrett, FRCPath*,
  4. S. Russell, MSc*,
  5. Hannah Wen, MD,
  6. Jianjun Wei, MD,
  7. Alex Laios, MD§,
  8. Sharon O'Toole, PhD§,
  9. M. Ring, BSc*,
  10. K. Denning, PhD*,
  11. J. Li, PhD*,
  12. S. Aherne, BSc*,
  13. D. Sammarae, MD§,
  14. N. A. Aziz, MD§,
  15. A. Alhadi, MD§,
  16. Sephen P. Finn, PhD,
  17. M. Loda, MD,
  18. Sheppard B, PhD§,
  19. Orla Sheils, PhD* and
  20. John J. O'Leary, MD, PhD*
  1. *From the Departments of Histopathology, and
  2. From the Departments of Obstetrics and Gynaecology, Trinity College, Dublin, Dublin, Ireland;
  3. From the Departments of Department of Pathology, Northwestern University, Chicago, IL;
  4. §From the Departments of Department of Pathology, New York University, New York, NY; and
  5. From the Departments of Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.
  1. Address correspondence and reprint requests to Dr. Richard Flavin, Department of Histopathology, Phase 3 Trinity Centre for Health Sciences, St James's Hospital, James's St, Dublin 8, Ireland. E-mail: flavinr{at}tcd.ie.

Abstract

Micro-RNAs are a group of small noncoding RNAs approximately 22 nucleotides in length. Recent work has shown differential expression of mature micro-RNAs in human cancers. We characterized the alteration in expression of miR-29b in ovarian serous carcinoma. miR-29b expression was analyzed using quantitative stem-loop reverse transcriptase polymerase chain reaction on a set of 50 formalin-fixed, paraffin-embedded ovarian serous carcinoma samples. Protein expression of p53, estrogen receptor, progesterone receptor, human epidermal growth factor receptor 2, Ki-67, and insulinlike growth factor 1 was quantified in the corresponding tissue microarray. The expression profile of miR-29b was correlated with clinicopathological and patient survival data. We provide definitive evidence that miR-29b is down-regulated in a significant proportion of ovarian serous carcinomas and is associated with specific clinicopathological features, most notably high miR-29b expression being associated with reduced disease-free survival.

  • Micro-RNA
  • Ovarian serous carcinoma
  • Biomarkers

Statistics from Altmetric.com

Footnotes

  • Disclosure/Conflict of Interest: Dr Richard Flavin is funded by an HRB Ireland Clinical Research Fellowship under Grant No. CRT/2006/10. The authors would like to acknowledge The Emer Casey Foundation Ireland.

  • The authors have no conflict of interest to disclose.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.